Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
Background: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxalta US Inc, a Takeda company, Lexington, MA, USA], is indicated for the treatment of bleeding episodes, perioperative management, and routine prophylaxis in patients w...
Main Authors: | Carmen Escuriola Ettingshausen, Cedric Hermans, Pål A. Holme, Ana R. Cid, Kate Khair, Johannes Oldenburg, Claude Négrier, Jaco Botha, Aurelia Lelli, Jerzy Windyga |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-07-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/20406207231184323 |
Similar Items
-
Management of a patient with factor X deficiency with FEIBA: a case report
by: Borboruah Luish, et al.
Published: (2023-08-01) -
Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
by: Francisco Ibarra, et al.
Published: (2022-04-01) -
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
by: Yesim Dargaud, et al.
Published: (2021-12-01) -
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 PROPEL study
by: Carmen Escuriola-Ettingshausen, et al.
Published: (2023-06-01) -
Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?
by: Evelien Krumb, et al.
Published: (2021-07-01)